Banco De Sabadell, S.A Bristol Myers Squibb CO Transaction History

Banco De Sabadell, S.A

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$61.91 - $67.42 $913,358 - $994,647	-14,753 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$59.34 - $66.74 $207,868 - $233,790	-3,503 Reduced 19.19%	14,753 $934,000
Q4 2020 Feb 12, 2021	SELL	$57.74 - $65.43 $268,721 - $304,511	-4,654 Reduced 20.31%	18,256 $1.13 Million
Q3 2020 Nov 13, 2020	SELL	$57.43 - $63.64 $2.6 Million - $2.88 Million	-45,212 Reduced 66.37%	22,910 $1.38 Million
Q2 2020 Aug 07, 2020	BUY	$54.82 - $64.09 $47,200 - $55,181	861 Added 1.28%	68,122 $3.98 Million
Q1 2020 May 14, 2020	BUY	$46.4 - $67.43 $2.1 Million - $3.06 Million	45,308 Added 206.39%	67,261 $3.71 Million
Q4 2019 Feb 14, 2020	BUY	$49.21 - $64.19 $157,472 - $205,408	3,200 Added 17.06%	21,953 $1.41 Million
Q3 2019 Nov 15, 2019	SELL	$42.77 - $50.71 $807,796 - $957,759	-18,887 Reduced 50.18%	18,753 $946,000
Q2 2019 Aug 13, 2019	BUY	$44.62 - $49.34 $246,525 - $272,603	5,525 Added 17.2%	37,640 $1.7 Million
Q1 2019 May 14, 2019	SELL	$45.12 - $53.8 $73,635 - $87,801	-1,632 Reduced 4.84%	32,115 $1.53 Million
Q4 2018 Feb 14, 2019	BUY	$48.76 - $63.23 $54,269 - $70,374	1,113 Added 3.41%	33,747 $1.72 Million
Q3 2018 Nov 16, 2018	BUY	$55.19 - $62.25 $11,148 - $12,574	202 Added 0.62%	32,634 $2.03 Million
Q2 2018 Aug 15, 2018	BUY	$50.53 - $62.98 $189,588 - $236,300	3,752 Added 13.08%	32,432 $1.79 Million
Q1 2018 May 16, 2018	SELL	$59.92 - $68.98 $59,500 - $68,497	-993 Reduced 3.35%	28,680 $1.81 Million
Q4 2017 Feb 16, 2018	BUY	$59.94 - $65.35 $1.78 Million - $1.94 Million	29,673	29,673 $1.82 Million

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Banco De Sabadell, S.A, based on Form 13F filings with the SEC.

Stay updated on Banco De Sabadell, S.A with notifications on news.